Trump Tariff and the Trade Turbulence – A Salil Kallianpur Blog

September 26, 2025

Impact of Trump’s 100% tariff on imported patented/innovative drugs and its implications for Indian pharma Trump announced a 100% tariff on branded/patented finished drugs not manufactured in the U.S., with exemptions only for those building U.S. manufacturing capacity. While the U.S. remains the hub for drug approvals, innovation is increasingly global with Europe hosting major…

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here

Hot this week

Topics

Eli Lilly’s $6.5 Billion Houston Bet: A Strategic Play in U.S. Manufacturing, Policy, and the Next Wave of Obesity Treatment

From VUCA to TACO: Thriving in a Chaotic World

Trump Tariff and the Trade Turbulence – A Salil Kallianpur Blog

Free Membership Required

Medical Reps—Lessons From The West: The Old Model is Dead

The Great Healthcare Pivot: Who Owns The Consumer Before They Become A Patient?

RPG-Raghava and Lessons From a Decade of Indian Pharma M&A

Pharmacy of the World Pricing Paradox

Why The Government Must Stop Playing Market Trader And Start Being The Sheriff

Topics

Medical Reps—Lessons From The West: The Old Model is Dead

The Great Healthcare Pivot: Who Owns The Consumer Before They Become A Patient?

RPG-Raghava and Lessons From a Decade of Indian Pharma M&A

Pharmacy of the World Pricing Paradox

Why The Government Must Stop Playing Market Trader And Start Being The Sheriff

MedicinMan Pharma Pulse: August 2026

GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?

How To See Dr Reddy’s Nestle In The Wellness Shift

Related Articles

The Great Healthcare Pivot: Who Owns The Consumer Before They Become A Patient?

RPG-Raghava and Lessons From a Decade of Indian Pharma M&A

Pharmacy of the World Pricing Paradox

Why The Government Must Stop Playing Market Trader And Start Being The Sheriff

GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?

Company

Headlines

Medical Reps—Lessons From The West: The Old Model is Dead

The Great Healthcare Pivot: Who Owns The Consumer Before They Become A Patient?

RPG-Raghava and Lessons From a Decade of Indian Pharma M&A

Pharmacy of the World Pricing Paradox

Newsletter